Nikhil C. Munshi, MD

Adjunct Associate Professor, Boston University Chobanian & Avedisian School of Medicine

Biography

Dr. Nikhil Munshi received his medical degree from Maharaja Sayajirao University, followed by an internship and residency in internal medicine at Shri Sayaji General Hospital and Maharaja University in India. He then completed an oncology fellowship at Johns Hopkins Ocology Center, and an hematology/oncology fellowhip at Indiana University Medical Center. Dr. Munshi is currently professor of medicine in the Department of Medicine at Harvard Medical School, as well as an attending physician at VA Boston Healthcare System and Dana-Farber Cancer Institute.

A diplomate of American Board of Internal Medicine, Dr. Munshi is also on the Board of Directors of the International Myeloma Society. He is a member of numerous professional associations including the Indian Medical Association, Physician’s Association of India, Indian Association of Clinical Oncology, American Medical Association, American Society of Clinical Oncology, and the American Society of Hematology, among others. In addition, he is on the editorial board of Clinical Lymphoma and Myeloma and Personalized Medicine in Oncology and is an ad hoc reviewer for numerous professional journals.

Dr. Munshi’s current laboratory research and clinical activities specialize in plasma cell disorders with a focus on understanding oncogenomic changes in myeloma and developing a translational research programs in myeloma. He has also established a Myeloma Initiative at Veterans Administration Hospitals, a comprehensive program bringing together, for the first time, all major VA hospitals across the country to focus on cutting-edge joint clinical studies.

Publications

  • Published 9/25/2026

    Sperling AS, Munshi NC. Crossing the Threshold to Cure in Multiple Myeloma. Cancer J. 2026 Sep-Oct 01; 32(5). PMID: 42809690.

    Read at: PubMed

  • Published 9/22/2026

    Lazzaro A, Nannini K, Yildirim C, Huhmann L, Culnan JM, Corrigan JK, Elbers D, Do NV, Brophy M, Munshi N, Fillmore NR, Edwards CV. Evolution of real-world frontline treatment patterns in multiple myeloma. Blood Adv. 2026 Sep 22; 10(18):6278-6288. PMID: 42480210.

    Read at: PubMed

  • Published 9/17/2026

    Schavgoulidze A, Cui J, Mayoral JE, Favasuli V, Talluri S, Maheo S, Cerutti C, Shammas M, Primo D, Vicente C, Larrayoz M, Martínez-Climent JA, Anderson KC, Aktas-Samur A, Samur MK, Avet-Loiseau H, Corre J, Munshi NC, Fulciniti M. PKMYT1 is a targetable vulnerability in del(17p) high-risk multiple myeloma. Blood. 2026 Sep 17; 148(12):1559-1571. PMID: 42237635.

    Read at: PubMed

  • Published 8/11/2026

    Ladisa F, Morelli E, Soncini D, Garibotto M, Munshi NC, Fulciniti M, Cea M. CRISPR application in hematological disorders: from bench to bedside. Blood Adv. 2026 Aug 11; 10(15):5350-5366. PMID: 42263664.

    Read at: PubMed

  • Published 8/3/2026

    Gallo Cantafio ME, Puccio N, Torcasio R, Valentino I, Ganino L, Jin Y, Aktas Samur A, Murfone P, Gallo A, Samur MK, Cuscino N, Giallongo C, Perrotta ID, Ciarrocchi A, Tallarigo F, De Francesco EM, Barbuto D, Jansen-van Vuuren RD, Jedlovcnik L, Wu D, Martino EA, Tibullo D, Di Raimondo F, Gentile M, Neri A, Archer SL, Morelli E, Munshi NC, Viglietto G, Fulciniti M, Amodio N. DRP1-mediated mitochondrial fragmentation is a druggable vulnerability in multiple myeloma. Blood. 2026 Aug 03. PMID: 42550764.

    Read at: PubMed

View All 662 Publications:   View Full Profile in BUMC

Websites

Education

  • Maharaja Sayajirao University, MBBS
  • Maharaja Sayajirao University, MD

View all profiles